ホーム>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>Meprednisone

Meprednisone (Synonyms: Methylprednisone, NSC 527579, SCH 4358)

カタログ番号GC15668

メプレドニゾンはグルココルチコイドであり、プレドニゾンのメチル化誘導体です。

Products are for research use only. Not for human use. We do not sell to patients.

Meprednisone 化学構造

Cas No.: 1247-42-3

サイズ 価格 在庫数 個数
5mg
$48.00
在庫あり
10mg
$69.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Meprednisone is a glucocorticoid and a methylated derivative of prednisone.Target: Glucocorticoid ReceptorMeprednisone is a glucocorticoid and a methylated derivative of prednisone. The methylprednisone to MPL area under the curve ratio decreased from 0.19 +/- 0.04 in control to 0.14 +/- 0.03 in ketoconazole-treated rats (P less than .05) due to altered interconversion between these steroids. An improved pharmacokinetic/dynamic receptor/gene-mediated model characterized the steroid receptor binding and induction of tyrosine aminotransferase activity after i.v. MPL sodium succinate (10 mg/kg). In contrast to previous in vitro studies, ketoconazole at maximally tolerated doses failed to antagonize the steroid receptor-mediated activity of MPL [1].

References:
[1]. Scheuer, E. and E. Warshaw, Allergy to corticosteroids: update and review of epidemiology, clinical characteristics, and structural cross-reactivity. Am J Contact Dermat, 2003. 14(4): p. 179-87.

レビュー

Review for Meprednisone

Average Rating: 5 ★★★★★ (Based on Reviews and 17 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Meprednisone

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.